Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The relatively new drugs the first being approved by the Food and Drug Administration (FDA) in 2005 also signal a significant shift in how hospitals and health systems treat chronic conditions such as type 2 diabetes and heart disease
Eli Lilly plans to introduce Mounjaro (tirzepatide) in India by 2025, while Biocon has made regulatory filings for GLP-1 receptor agonists in various markets, including India, to expand its portfolio in the obesity and diabetes treatment segments
Researchers interviewed 30 participants from 15 states, including men, women, and one nonbinary participant, all with diverse racial and ethnic backgrounds
Eli Lilly raised Mounjaros UK list price from September 2025 to bring it closer to pricing in other countries
You won't want to miss out on the chance to participate alongside fellow Reframers (or solo if that's more your thing!)
US$ 22.36
US$ 22.16
US$ 28.72
US$ 27.28
US$ 27.30
US$ 25.10
